Investing.com - Astria Therapeutics (NASDAQ: ATXS) reported first quarter EPS of $-0.400, $0.17 better than the analyst estimate of $-0.570. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Astria Therapeutics's stock price closed at $12.110. It is down -18.340% in the last 3 months and up 200.500% in the last 12 months.
Astria Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Astria Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Astria Therapeutics's Financial Health score is "fair performance".
Check out Astria Therapeutics's recent earnings performance, and Astria Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar